Rigel Pharmaceuticals, Inc. Forecast, price target & analysts
Rigel Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Rigel Pharmaceuticals, Inc. Classifications & Recommendation:
Rigel Pharmaceuticals, Inc. Price Target
| Target Price | $23.97 |
| Price | $19.48 |
| Potential |
23.05%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Rigel Pharmaceuticals, Inc. 2026 .
The average Rigel Pharmaceuticals, Inc. target price is $23.97.
This is
23.05%
register free of charge
$59.85
207.24%
register free of charge
$20.65
6.03%
register free of charge
|
|
| A rating was issued by 12 analysts: 7 Analysts recommend Rigel Pharmaceuticals, Inc. to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Rigel Pharmaceuticals, Inc. stock has an average upside potential 2026 of
23.05%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 179.28 | 205.12 |
| 53.39% | 14.41% | |
| EBITDA Margin | 14.74% | 14.05% |
| 189.48% | 4.66% | |
| Net Margin | 9.76% | 10.28% |
| 145.45% | 5.37% |
8 Analysts have issued a sales forecast Rigel Pharmaceuticals, Inc. 2025 . The average Rigel Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Rigel Pharmaceuticals, Inc. EBITDA forecast 2025. The average Rigel Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Rigel Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Rigel Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.99 | 1.18 |
| 168.75% | 19.19% | |
| P/E | 16.51 | |
| EV/Sales | 1.61 |
8 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast for earnings per share. The average Rigel Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Rigel Pharmaceuticals, Inc....
Current Rigel Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Mar 05 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 05 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 23 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 22 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 14 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Mar 05 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 05 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 23 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 22 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 14 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
